CN100360159C - Kidney benefiting, Chong collateral reinforcing and menstruation regulating hemostat - Google Patents
Kidney benefiting, Chong collateral reinforcing and menstruation regulating hemostat Download PDFInfo
- Publication number
- CN100360159C CN100360159C CNB2004100198786A CN200410019878A CN100360159C CN 100360159 C CN100360159 C CN 100360159C CN B2004100198786 A CNB2004100198786 A CN B2004100198786A CN 200410019878 A CN200410019878 A CN 200410019878A CN 100360159 C CN100360159 C CN 100360159C
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- portions
- blood
- capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000005906 menstruation Effects 0.000 title claims abstract description 36
- 210000003734 kidney Anatomy 0.000 title claims abstract description 32
- 230000001105 regulatory effect Effects 0.000 title claims abstract description 17
- 230000003014 reinforcing effect Effects 0.000 title abstract 2
- 239000002874 hemostatic agent Substances 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract description 59
- 239000008187 granular material Substances 0.000 claims abstract description 9
- 235000004879 dioscorea Nutrition 0.000 claims abstract description 4
- 239000002775 capsule Substances 0.000 claims description 63
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 11
- 241000180649 Panax notoginseng Species 0.000 claims description 11
- 230000000087 stabilizing effect Effects 0.000 claims description 11
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 10
- 210000000582 semen Anatomy 0.000 claims description 10
- 229940030225 antihemorrhagics Drugs 0.000 claims description 8
- 230000000025 haemostatic effect Effects 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 4
- 235000005903 Dioscorea Nutrition 0.000 claims description 3
- 241000234273 Dioscorea Species 0.000 claims description 3
- 235000000504 Dioscorea villosa Nutrition 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 97
- 239000008280 blood Substances 0.000 abstract description 97
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 21
- 239000000843 powder Substances 0.000 abstract description 15
- 239000002994 raw material Substances 0.000 abstract description 5
- 239000006187 pill Substances 0.000 abstract description 4
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 3
- 239000007902 hard capsule Substances 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 239000002674 ointment Substances 0.000 abstract 2
- 241000427159 Achyranthes Species 0.000 abstract 1
- 241000173529 Aconitum napellus Species 0.000 abstract 1
- 244000233890 Alisma plantago Species 0.000 abstract 1
- 235000017300 Alisma plantago Nutrition 0.000 abstract 1
- 241000202726 Bupleurum Species 0.000 abstract 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 abstract 1
- 235000002991 Coptis groenlandica Nutrition 0.000 abstract 1
- 244000247747 Coptis groenlandica Species 0.000 abstract 1
- 235000003805 Musa ABB Group Nutrition 0.000 abstract 1
- 240000008790 Musa x paradisiaca Species 0.000 abstract 1
- 240000005001 Paeonia suffruticosa Species 0.000 abstract 1
- 235000003889 Paeonia suffruticosa Nutrition 0.000 abstract 1
- 235000002789 Panax ginseng Nutrition 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 abstract 1
- 244000248825 Peltandra virginica Species 0.000 abstract 1
- 235000001188 Peltandra virginica Nutrition 0.000 abstract 1
- 235000015266 Plantago major Nutrition 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 240000006079 Schisandra chinensis Species 0.000 abstract 1
- 235000008422 Schisandra chinensis Nutrition 0.000 abstract 1
- 235000017803 cinnamon Nutrition 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 238000011282 treatment Methods 0.000 description 68
- 230000000694 effects Effects 0.000 description 54
- 238000012360 testing method Methods 0.000 description 43
- 208000024891 symptom Diseases 0.000 description 34
- 208000032843 Hemorrhage Diseases 0.000 description 29
- 210000004291 uterus Anatomy 0.000 description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 25
- 206010013908 Dysfunctional uterine bleeding Diseases 0.000 description 24
- 241000700159 Rattus Species 0.000 description 21
- 230000000740 bleeding effect Effects 0.000 description 20
- 230000003203 everyday effect Effects 0.000 description 20
- 208000004998 Abdominal Pain Diseases 0.000 description 19
- 201000010099 disease Diseases 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 17
- 206010027514 Metrorrhagia Diseases 0.000 description 16
- 230000003780 keratinization Effects 0.000 description 16
- 210000004185 liver Anatomy 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 230000027758 ovulation cycle Effects 0.000 description 15
- 210000001215 vagina Anatomy 0.000 description 15
- 240000007711 Peperomia pellucida Species 0.000 description 14
- 208000002173 dizziness Diseases 0.000 description 14
- 230000037396 body weight Effects 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 210000000981 epithelium Anatomy 0.000 description 13
- 208000007106 menorrhagia Diseases 0.000 description 13
- 239000000284 extract Substances 0.000 description 12
- 230000003821 menstrual periods Effects 0.000 description 12
- 230000023597 hemostasis Effects 0.000 description 11
- 210000001672 ovary Anatomy 0.000 description 11
- RJKFOVLPORLFTN-LEKSSAKUSA-N progesterone group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 11
- 230000003248 secreting effect Effects 0.000 description 11
- 206010053567 Coagulopathies Diseases 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 206010024264 Lethargy Diseases 0.000 description 10
- 230000036760 body temperature Effects 0.000 description 10
- 230000035602 clotting Effects 0.000 description 10
- 230000002496 gastric effect Effects 0.000 description 10
- 238000001802 infusion Methods 0.000 description 10
- 206010000087 Abdominal pain upper Diseases 0.000 description 9
- 210000002919 epithelial cell Anatomy 0.000 description 9
- 230000008859 change Effects 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- 210000000265 leukocyte Anatomy 0.000 description 8
- 238000012545 processing Methods 0.000 description 8
- 238000011084 recovery Methods 0.000 description 8
- 210000002700 urine Anatomy 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 7
- 230000002513 anti-ovulatory effect Effects 0.000 description 7
- 230000007812 deficiency Effects 0.000 description 7
- 210000004696 endometrium Anatomy 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 230000003118 histopathologic effect Effects 0.000 description 7
- 230000010354 integration Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 230000004089 microcirculation Effects 0.000 description 7
- 230000036407 pain Effects 0.000 description 7
- 230000010412 perfusion Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000012109 statistical procedure Methods 0.000 description 7
- 210000001550 testis Anatomy 0.000 description 7
- 210000003462 vein Anatomy 0.000 description 7
- 238000005303 weighing Methods 0.000 description 7
- 206010002659 Anovulatory cycle Diseases 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 6
- 230000002051 biphasic effect Effects 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 210000003679 cervix uteri Anatomy 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 206010016256 fatigue Diseases 0.000 description 6
- 210000004907 gland Anatomy 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 230000029849 luteinization Effects 0.000 description 6
- 238000011121 vaginal smear Methods 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 5
- 208000031975 Yang Deficiency Diseases 0.000 description 5
- 210000001015 abdomen Anatomy 0.000 description 5
- 210000004100 adrenal gland Anatomy 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 230000002357 endometrial effect Effects 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 230000002489 hematologic effect Effects 0.000 description 5
- 230000003907 kidney function Effects 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000000630 rising effect Effects 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- -1 drying Substances 0.000 description 4
- 201000006828 endometrial hyperplasia Diseases 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 230000000762 glandular Effects 0.000 description 4
- 206010020718 hyperplasia Diseases 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 230000003908 liver function Effects 0.000 description 4
- 231100001252 long-term toxicity Toxicity 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000000386 microscopy Methods 0.000 description 4
- 231100000957 no side effect Toxicity 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000000186 progesterone Substances 0.000 description 4
- 229960003387 progesterone Drugs 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- 230000003639 vasoconstrictive effect Effects 0.000 description 4
- 210000001835 viscera Anatomy 0.000 description 4
- 206010003694 Atrophy Diseases 0.000 description 3
- 206010020565 Hyperaemia Diseases 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 206010020880 Hypertrophy Diseases 0.000 description 3
- 206010021137 Hypovolaemia Diseases 0.000 description 3
- 206010022998 Irritability Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 3
- 235000011613 Pinus brutia Nutrition 0.000 description 3
- 241000018646 Pinus brutia Species 0.000 description 3
- 208000028017 Psychotic disease Diseases 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 230000037444 atrophy Effects 0.000 description 3
- 230000002146 bilateral effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 235000013351 cheese Nutrition 0.000 description 3
- 210000004246 corpus luteum Anatomy 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 238000013401 experimental design Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000002607 hemopoietic effect Effects 0.000 description 3
- 230000001788 irregular Effects 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 230000000938 luteal effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 210000003097 mucus Anatomy 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000016087 ovulation Effects 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 208000037920 primary disease Diseases 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000035752 proliferative phase Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000003809 water extraction Methods 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 208000019802 Sexually transmitted disease Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940126678 chinese medicines Drugs 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 210000000918 epididymis Anatomy 0.000 description 2
- 201000010063 epididymitis Diseases 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 210000002570 interstitial cell Anatomy 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- BALXUFOVQVENIU-KXNXZCPBSA-N pseudoephedrine hydrochloride Chemical compound [H+].[Cl-].CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-KXNXZCPBSA-N 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000002562 urinalysis Methods 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000521257 Hydrops Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000005775 Parakeratosis Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 206010051986 Pneumatosis Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000053227 Themus Species 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 229940046358 diethylstilbestrol 0.1 mg Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000009592 kidney function test Methods 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 210000004158 stalk cell Anatomy 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000013948 uterine smooth muscle contraction Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a medicine for benefiting kidneys, reinforcing actuation, regulating menstruation and stopping blood, which comprises the raw materials of prepared rehmanniae roots, panax pseudo-ginseng, tuckahoe, achyranthes roots, plantain seeds, schisandra fruits, bupleurum roots, cinnamon, water plantain, Chinese yams, coptis, tree peony barks and monkshood. After the traditional Chinese medicines are respectively extracted with water, pulverized, etc. according to different characteristics, the traditional Chinese medicines are proportionally prepared to make into hard capsules, tablets, drop pills, pills, granules, powder, decocted ointment, fluidextract and soaked ointment. The present invention has notable therapeutic effect.
Description
Technical field
The present invention relates to a kind of kidney tonifying CHONG meridian stabilizing and menstruation regulating haemostatic medicament compositions, particularly relating to a kind of kidney tonifying CHONG meridian stabilizing and menstruation regulating hemostasis that with the vegetable Chinese herbal medicine is raw material is made is used for because of deficiency of the liver and kindey, menorrhagia due to the Chong and Ren channel disorder, abdominal pain in menstruation, the adolescence dysfunctional uterine bleeding, last ring back metrorrhagia person's medicine and preparation thereof.
Background technology
At present, disclosed have June 4 1998 applying date about kidney tonifying CHONG meridian stabilizing and menstruation regulating haemostatic medicament and preparation thereof, and publication number 1203805 " a kind of health beverage of the woman's of control menopathy " is to be made by 29 flavor Chinese medicines; On June 10 1998 applying date, publication number 1206611 " Fukang granule for women of calming the nerves " is to be made by 20 flavor Chinese medicines, and flavour of a drug are many, cause the cost height.
Summary of the invention
The objective of the invention is to prepare the hemostasis of kidney tonifying CHONG meridian stabilizing and menstruation regulating with medicine of selecting meticulously and best proportioning is used for because of deficiency of the liver and kindey, menorrhagia due to the Chong and Ren channel disorder, abdominal pain in menstruation, adolescence dysfunctional uterine bleeding, last ring back metrorrhagia person's medicine and preparation thereof.
Solution of the present invention is based on motherland's medical science to menorrhagia, sick pathogenetic understanding of abdominal pain in menstruation and Therapeutic Principle, and the screening hemostasis, the pain relieving and the plant amedica of enriching blood by the theory of Chinese medical science prescription, skim the cream off milk, and make its performance kidney tonifying CHONG meridian stabilizing and menstruation regulating hemostatic effect.
(consumption is a weight portion) that medicine of the present invention also can be made by following component: 3～12 parts of Cortex Moutan 10-40 of Radix Rehmanniae Preparata 30-120 part Semen Plantaginis 12-48 part Poria 15～60 parts of Radix Bupleuri 10-40,6～24 portions of Rhizoma Alismatis of 15～60 portions of Cortex Cinnamomis of 15～60 parts of Fructus Schisandrae Chinensis of part Radix Achyranthis Bidentatae 10～40 portions of Radix Notoginseng 10-40 12～48 portions of Rhizoma Coptidis of 6～24 portions of Rhizoma Dioscoreaes of part Radix Aconiti Lateralis Preparata part
The optimum weight proportioning of medicine of the present invention is:
20 parts of 6 parts of Cortex Moutans of 30 parts of Fructus Schisandrae Chinensis of 20 parts of Radix Achyranthis Bidentataes of 30 parts of Radix Bupleuri of 24 parts of Poria of 60 portions of Semen Plantaginiss of Radix Rehmanniae Preparata, 24 portions of Rhizoma Coptidis of 12 portions of Rhizoma Dioscoreaes of 20 parts of Radix Aconiti Lateralis Preparatas of 20 portions of Radix Notoginseng of 12 portions of Rhizoma Alismatis of 30 parts of (system) Cortex Cinnamomis
With above-mentioned each component preparation cost invention medicine production method be: above 13 flavors, Radix Aconiti Lateralis Preparata, Radix Notoginseng, Radix Bupleuri, Cortex Cinnamomi, Rhizoma Coptidis powder are broken into fine powder, sieve mixing; Eight flavors such as all the other Radix Rehmanniae Preparata, Fructus Schisandrae Chinensis decoct with water three times, and 3 hours for the first time, 6 times of water gagings; 2 hours for the second time, 5 times of water gagings; 1 hour for the third time, 4 times of water gagings; Merging filtrate is condensed into relative density and is 1.25～1.30 thick paste, with above-mentioned powder mixing, makes granule, drying, and granulate incapsulates, promptly.Simultaneously, also can be made into soft capsule, tablet, drop pill, pill, granule, powder, soft extract, fluid extract and extractum.
Kidney tonifying CHONG meridian stabilizing and menstruation regulating haemostatic medicament of the present invention (also claiming " spring blood peace capsule ") has kidney tonifying Gu Chong, the regulating menstruation, hemostasis function through spring blood peace capsule pharmacological research, long term toxicity, evidence kidney tonifying CHONG meridian stabilizing and menstruation regulating haemostatic medicament such as clinical.Can be used for curing mainly: because of deficiency of the liver and kindey, the menorrhagia due to the Chong and Ren channel disorder, abdominal pain in menstruation, the adolescence dysfunctional uterine bleeding, last ring back metrorrhagia person's good medicine, and have no side effect.Test is as follows in detail:
Spring blood peace capsule pharmacological research
Summary: spring blood peace capsule is mainly used in treatment renal deficiency type adolescence dysfunctional uterine bleeding in clinical.Pharmacological experiment study shows that spring blood peace capsule gastric infusion can obviously shorten clotting time of mice; In stripped rabbit ear perfusion experiment, spring blood peace capsule has tangible vasoconstrictive effect; In the test of isolated rat uterus, can strengthen the irritability in uterus, strengthen its contractility.Through repeatedly gastric infusion mouse vagina plate coating checking and histopathologic examination, find that spring blood peace capsule can obviously improve mouse vagina epithelial cell keratinization rate, the vagina epithelium layer is thickened, basal layer cell and middle layer cells increase, and the epithelium keratinization is complete; Spring blood peace capsule repeatedly gastric infusion obviously increases mouse uterine weight.Histopathologic examination finds, makes the endometrium of mouse hypertrophy, presents secretory endometrium and changes.In sum, spring blood peace capsule clotting time by shortening, and vasoconstrictive improves the endocrine disturbance, regulate hormone level, and reach the purpose of treatment " anovulatory dysfunctional uterine hemorrhage ".
Test material
Medicine: the spring, blood peace capsule Tianjin Hongrentang Pharmaceutical Co., Ltd. provided.1g capsule medicated powder) and 1: 2 solution capsule medicated powder is boiled through twice 30 minutes warm fire, merge and to be made into 1: 1 solution (1ml solution:, be for experiment after decoct filters.
Animal: mice: the Kunming kind, female, body weight is shown test and is decided.
Rat: the wistar kind, female, body weight is shown test and is decided.
Rabbit: big white, female, the male dual-purpose of ear, body weight 2-3kg.
Test method and result:
One, blood is pacified the influence of capsule to clotting time of mice:
Get 30 of Healthy female mices, body weight 18-22g is divided into 2 groups at random, 15 every group.Spring blood peace administration group one twice-daily is irritated stomach and is given 1: 1 spring blood peace solution 28.8g/kg.Matched group gives distilled water, with reference to slide method
[1]Cut off the Mus tail, get one and bleed, the immediate record clotting time the results are shown in Table 1.
Table 1 spring blood peace capsule is to the influence of clotting time of mice
* P＜0.01 (comparing) with matched group
Table 1 is the result show, clotting time of mice can be obviously shortened in spring blood peace capsule one twice-daily administration.
Two, spring blood is pacified the influence of capsule to the rabbit ear perfusion that exsomatizes:
6 of rabbit are selected in test for use,, the male and female dual-purpose.Every rabbit is selected the edge vein of picking up the ears for use, makes 6 specimen.Rabbit pentobarbital sodium (40mg/kg) ear vein is anaesthetized.The abdomen position is fixed on the operating-table, cuts off the hair of auris dextra root, and in rabbit ear convex surface center, as seen printing opacity has thick blood vessel to pass through.The larynx blood vessel moves towards to cut skin 2-3cm, separates subcutaneous tissue, promptly visible rabbit ear vein (central vein), and rabbit ear tremulous pulse is separated than the depths in parallel position with vein.The careful about 2cm length of rabbit ear tremulous pulse of separating is worn two rhizoid lines under it, the ligation near-end, and one " V " shape otch is made in the ligation distally again.The indenting ball that will be full of the syringe of Rockwell liquid and connect rubber tube inserts tremulous pulse rapidly, cuts off vein after the ligation, injects the blood that retains in the Rockwell liquid flushing blood vessel to intra-arterial, till effusive liquid is colourless.In the anesthesia of basal part of the ear surrounding injection procaine, cut the rabbit ear, the rabbit ear is fixed on five jiaos of glass plates, with 45 this plate is tilted to be fixed on the retort stand, rabbit ear arterial cannulation links to each other with the perfusion bottle of containing Rockwell liquid through rubber tube.Perfusate in water bath with thermostatic control to 37 ℃ and pass to mist.Regulate the rubber tube screw clamp, make the effusive perfusate of rabbit ear vein under glass plate angular flux, flow speed control is dripped number with the stopwatch record about 30 droplets/minute.Treated after the constant flow rate continuous record 3 minutes, its meansigma methods is a control value before the administration, slowly injects 1: 2 spring blood peace solution 1ml then from the intubate top, write down 3 minutes flow velocitys and gets its average and compare with administration is preceding, the results are shown in Table 2.
Table 2 spring blood peace capsule is to the influence of the rabbit ear perfusion flow that exsomatizes
| Medicine | Number of samples (individual) | Rabbit ear perfusion flow (drip/minute) | |
| Before the administration | After the administration | ||
| Spring blood peace | 6 | 31.83±5.33 | 26.50±6.88** |
* P＜0.01 (self compares before and after the administration)
Table 2 is the result show, 1: 2 spring blood peace solution can obviously reduce rabbit ear perfusion flow, has tangible vasoconstrictive effect.
Three. spring blood is pacified the influence of capsule to the isolated rat uterus:
[3]
8 of unpregnancy female rats, body weight 180-230g are selected in test for use.Tested preceding 1 day, subcutaneous injection diethylstilbestrol 0.1mg/kg puts to death rat next day.Take out the uterus immediately and be dipped in the nutritional solution, nutritional solution adopts Geneu improvement tyrode's solution.
[2]Choose cornua uteri and make 16 specimen, the water bath with thermostatic control temperature is 37 ± 0.5 ℃, and nutritional solution is used 15ml at every turn, feeds O
2Then the uterus specimen is connected on the lever adjustment of tonicity.The back adds 1: 1 spring blood peace solution 0.2ml to treat to shrink the uterus specimen steadily, traces uterus specimen contractile motion, the results are shown in Table 3.
Table 3 spring blood peace capsule is to the influence of isolated rat uterine smooth muscle contraction movement
"+" expression increases less than 50%, and " ++ " expression increases 50-100%, " +++" increase greater than 100%.
Table 3 is the result show, adds 1: 1 spring blood peace solution 0.2ml isolated rat uterine smooth muscle irritability is strengthened, and tension force increases, and amplitude strengthens.But to not obviously influence of frequency.
Four, spring blood is pacified the influence of capsule to vaginal epithelial cell:
[4]
Choose the Healthy female mice, body weight 18-22g.All extract ovary, make vaginal smear examination, choose and be dioestrus 60 of mices in continuous 5 days.Be divided into 20 of 40 of administration groups and matched groups at random.The administration group is irritated stomach and given 28.8g/kg1: 1 spring blood peace solution, matched group gives distilled water, successive administration 15 days.All made vaginal smear examination behind the self administration of medication in the 5th day to the 15th day.Observing mouse vagina epithelial cell keratinization rate and histopathology changes.The results are shown in Table 4.
Table 4 spring blood peace capsule is to the influence of mouse vagina epithelial cell keratinization rate
Table 4 result as seen, observe through the mouse vagina smear, the 8th day begins to occur changing after the administration, vaginal smear epithelial cell keratinization rate obviously improves, and being higher than 60% (height keratinization) has 10, and being lower than 60% (moderate keratinization) has 13, be lower than 30% (low keratinization) and have 13, between administration 8-10 days, mouse vagina epithelial cell keratinization rate obviously increases, and estrogen is in more than the medium level.The 8th day above level of moderate keratinization rate accounts for 36 and merely hit 23 to account for to account in 63.9%, the 9 day and accounted for 50% in 61%, the 10 day, and mouse vagina epithelial cell keratinization rate reduces gradually afterwards, accounts for 78.6% to the 15th day low keratinization.And matched group is the dioestrus change always, does not show the cycle variation.
Through histopathologic examination's discovery, put to death 8 mices on the 10th day after the administration, microscopy finds that the vagina epithelium layer thickens, and substrate stalk cell and middle layer cells increase, and the epithelium keratinization is complete or relatively more complete.Partially sliced visible cell silk splits phenomenon.And control group mice vagina epithelium layer is thinner, cells of superficial layer parakeratosis, and middle layer cells is bigger, and a matter is accompanied a large amount of leukocyte.Put to death whole mices after the administration on the 15th day, microscopy finds, except that 6 mouse vagina epithelial cell keratinization fully, all the other present vagina epithelium hamartoplasia more, but maturity is lower.Middle layer cells is thicker, and epithelium cells of superficial layer nuclear is bigger, is not differentiation fully.The cuticular layer on surface is rare, the more visible leukocyte of a matter.The microscopy result of matched group is consistent with the 10th day.
Five, spring blood is pacified the influence of capsule to uterus weight:
The female mice of extracing ovary is selected in test for use, and 18-22g is divided into three groups at random, and 15 of administration groups are irritated stomach by 28.8g/kg and given 1: 1 spring blood peace solution, and 15 of matched groups give distilled water, successive administration 15 days.9 of Progesterone groups, intramuscular injection every day 0.2mg/, successive administration 5 days.All after the last administration, put to death mice, win the uterus, weigh and the uterus weight in wet base, obtain the ratio of uterus weight in wet base (mg)/10g body weight, the results are shown in Table 5.
Table 5 spring blood peace capsule is to the influence of mouse uterine weight
△ △ P＜0.01, * P＜0.01 (comparing with matched group) (Progesterone and spring blood peace group are relatively) is table 5 result show, spring blood peace and Progesterone administration group and matched group more all can obviously increase the uterus weight in wet base of extracing the ovary mice, and the Progesterone group is better than spring blood peace administration group.
Six, spring blood is pacified endometrial influence:
After the above-mentioned off-test, in uterus stuck-at-0% formalin solution, paraffin section, endometrial variation is examined under a microscope in H.E dyeing.Put to death 8 mices of spring blood peace group on the 10th day after the administration, microscopy is found endometrial hyperplasia, and epithelium is high column, and nucleus occupies basilar part, the Interstitial cell dense arrangement.Put to death whole mices on the 15th day after the administration, spring blood peace group endometrium is the secretory phase change, and glandular epithelium is the doll shape, and nuclear cavity down appears in basal cell, and nuclear moves to the middle part, and the body of gland growth is short helical form bending, the visible secretions of part lumen of gland.Between matter more loose, cell is big slightly, endochylema is abundanter; The Progesterone group, neointimal hyperplasia is obvious, and glandular epithelium is the doll shape, the glandular tube hypertrophy, body of gland is long helical form.More be apparent that than spring blood peace group, the lumen of gland expansion, secretory activity is vigorous, and a matter is loose, and cell increases, and endochylema is abundant and transparent; And the attenuation of matched group endometrium, the cubic body of gland of glandular epithelium is arranged closely, and Interstitial cell is little, dense arrangement.Change as seen from the uterus, spring blood peace administration can present the inner membrance performance of propagation phase in early days, and the secretory endometrium similar to the Progesterone effect appearred on the 15th day in post-drug period to be changed.
Conclusion (of pressure testing): above pharmacological testing proves that spring blood peace capsule gastric infusion obviously shortens clotting time of mice; Spring blood peace has tangible vasoconstrictive effect in stripped rabbit ear perfusion experiment; In the test of isolated rat uterus, can strengthen the irritability in uterus, strengthen strength of uterine contraction; Through repeatedly gastric infusion mouse vagina plate coating checking and histopathologic examination, find how spring blood obviously improves mouse vagina epithelial cell keratinization rate.The vagina epithelium layer is thickened, and basal layer cell and middle layer cells increase, and the epithelium keratinization is complete; Spring blood peace capsule repeatedly gastric infusion obviously increases the Mouse Uterus weight in wet base, and histopathologic examination is carried out in the uterus, finds that spring blood peace can make the endometrium of mouse hypertrophy present secretory endometrium and change, and this variation is similar to the Progesterone effect.
Spring snow peace capsule long term toxicity test
Summary is entrusted by Jianjin Pharmaceutical Factory No. 5 of Traditional Chinese Medicines, observes spring snow peace capsule to rat continuous oral administration 90 long term toxicity tests.The result shows: each organizes body weight, biochemical indicator, hematological indices and the pathological observation of experimental animal.Toxic reaction does not all appear.100 times of high dose group behaviour clinical treatment amount.For clinical application safety and draft the human safe dose reference is provided.
Experiment material
One, animal: Wistar rat, 6 ages in week, body weight 90 ± 10g, totally 80 of male and female half and half.Available from Chinese Academy of Medical Sciences animal feeding center.The quality certification: the moving word 01-3008 raising condition of doctor: 5 in every cage, male and female divide supports.20 ℃-24 ℃ of room temperatures.Feeds utilized available from Chinese Academy of Medical Sciences animal feeding center.Drinking water is a tap water.
Two, medicine: spring snow peace capsule is provided by Tianjin Hongrentang Pharmaceutical Co., Ltd..Lot number: 000301
Three, instrument: the TBA-30FR of Toshiba biochemical instruments, Japanese blood counting instrument F-800.
Experimental technique
(1) dosage and grouping: divide four groups at random with the Wistar rat, 20 every group, male and female half and half.That is:
1, matched group: the distilled water that waits capacity
2, high dose group: 12g/kg
3, middle dosage group: 6g/kg
4, low dose group: 3g/kg
(2) route of administration and method:
Be mixed with suspension with distilled water and be used for gastric infusion.Volume 2ml/100g, be administered once every day, every morning 8:30-10:00, seven times weekly, successive administration 3 months (90 days).
(3) observation and test item:
1, overview: variations such as food-intake, body weight, behavioral activity, outward appearance sign, feces character.Administration front side body weight, routine weighing and adjust dosage (according to body weight change) weekly after the administration.
2, hematological indices: erythrocyte (RBC) counting, leukocyte (WBC) sum and classification, hemoglobin (Hb), platelet (Pit) clotting time (CT) are measured.
3, blood parameters:
Asparagine based transferase (GOT), alanine aminotransferase (GPT), alkali phosphatase (ALP), blood urea nitrogen (BUN), total protein (TP) albumin (ALB) blood glucose (GLU), total bilirubin (T-BTL), creatinine (Grea), T-CHOL (T-CHO)
4, system becomes celestial and histopathologic examination:
After used big genus becomes celestial and checks, take off the row histoorgan and do histological examination: the heart, liver, spleen, lung, kidney, stomach, duodenum, small intestinal, colon, adrenal gland, thymus, thyroid, pancreas, brain, hypophysis, breastbone, bladder, lymph node, testis, (attached testis) prostate, uterus, ovary, its center, liver, spleen, lung, kidney, adrenal gland, testis, (attached testis), uterus, (ovary), brain is weighed and calculate organ coefficient.
5, each index determining time:
At experiment the 90th day, each treated animal of etherization.Abdomen master A gets blood, and (about 2/3 is 12; 14 days (about 1/3 is 8) above-mentioned every indexs of complete detection are observed in drug withdrawal.
Experimental result:
1, overview:
Activities in rats, food-intake is normal, feces is normal, and each organizes the body weight no significant difference.(P＞0.05) is as table 6
2, hematological examination: compare with matched group, the equal no significant difference of the every index of each administration group (P＞0.05) is as table 7,8
3, blood biochemical analysis: each organizes the equal no significant difference of every blood biochemistry index (P＞0.05) as table 9,10
4, internal organs inspection:
It is all normal that each organizes every internal organs system, and no significant difference (P＞0.05) is as table 11,12
5, histopathologic examination:
(1) perusal: matched group and high, medium and low three each rat of dosage group are normal by hair, skin, crissum is not seen secretions, and breast, abdominal cavity do not see that pneumatosis, hydrops, serous coat are smooth, do not see the petechia, and each internal organs position is as usual.Perusal does not see that work becomes, and cuts off skull, and meninges and brain do not see that work becomes.
(2) histological examination: matched group and high, medium and low three dosage group rats are examined internal organs and the body of gland heart, liver, spleen, lung, kidney, stomach, brain, ileum, colon, bladder, uterus, ovary, testis, prostate, thymus, hypophysis, adrenal gland, thyroid etc. and there is no work and become.Part animal lung, kidney have the mild inflammation sexually transmitted disease (STD) to become, and are general pathological change, and not seeing has the specificity pathological change.Pathological changes does not have obvious degree difference between each group.(attached: pathology photo 1-22# is a matched group; 23-44# ties up high dose group)
Conclusion: 3 months rat long term toxicity tests of spring blood peace capsule.The result shows: rat dosage (high dose group) is 100 times of people's clinical treatment dosage, and successive administration did not see that obvious toxicity appearred in animal in 90 days.Pointed out the safety of clinical practice.
Experimental unit: Tianjin medical science institute pharmacology two Room study director: Li Meng
Experimenter: Li Meng, Wang Yan, Nie Wei, Wang Li, Guan Jingfang, Bao Huairu
Table 6 spring is learned the influence (X ± SD, n=12 or n=8) of peace capsule to rat body weight
| Group | Body weight change X ± SD (g) before and after the administration, n=12 | 14 days n=8 after the drug withdrawal | |||||||||||||
| 0 week | 1 week | 2 weeks | 3 weeks | 4 weeks | 5 weeks | 6 weeks | 7 weeks | 8 weeks | 9 weeks | 10 weeks | 11 weeks | 12 weeks | 13 weeks | 15 weeks | |
| Matched group | 87.0 ±9.3 | 95.6 ±15.8 | 114.7 ±23.6 | 123.9 ±24.8 | 140.1 ±22.9 | 157.1 ±35.4 | 171.1 ±34.8 | 186.1 ±35.6 | 195.4 ±45.9 | 210.1 ±45.1 | 226.0 ±47.9 | 249.8 ±51.8 | 276.5 ±52.3 | 299.9 ±50.9 | 319. 1 ± 57.7 |
| High dose | 84.2 ±8.5 | 99.5 ±17.3 | 118.3 ±27.4 | 130.7 ±25.3 | 148.3 ±26.4 | 163.4 ±25.1 | 178.2 ±36.4 | 187.6 ±34.5 | 195.8 ±29.6 | 209.5 ±26.8 | 236.8 ±40.9 | 251.3 ±45.2 | 281.3 ±42.0 | 294.4 ±48.6 | 310. 8 ± 66.3 |
| Middle dosage | 85.2 ±9.0 | 105.1 ±15.6 | 120.7 ±28.9 | 134.5 ±28.5 | 150.3 ±23.8 | 163.6 ±29.7 | 174.6 ±37.2 | 180.1 ±35.1 | 199.1 ±45.5 | 204.8 ±38.1 | 222.5 ±39.9 | 255.3 ±36.9 | 273.6 ±41.3 | 285.6 ±52.4 | 302. 1 ± 45.8 |
| Low dosage | 86.1 ±14.6 | 94.7 ±14.6 | 114.8 ±21.7 | 129.6 ±20.4 | 143.9 ±25.8 | 158.7 ±24.9 | 168.6 ±35.7 | 180.7 ±35.3 | 192.9 ±35.8 | 218.4 ±45.3 | 243.9 ±32.1 | 251.8 ±45.0 | 278.2 ±42.7 | 292.8 ±53.4 | 315. 4 ± 49.7 |
Compare no significant difference (P＞0.05) with matched group
Table 7 spring is learned the influence (X ± SD, n=12 are only) to the every hematological indices of rat after 90 days of the continuous gastric infusion of peace capsule
| Group | Hemogram | The WBC classification | Clotting time | ||||
| RBC×10 12 | Hbg/l | Pit×10 9/l | WBC×10 9/l | Neutral % | Lymph % | CT(S) | |
| Matched group | 7.1±0.8 | 139.0±17.6 | 420.5±49.3 | 13.5±3.9 | 0.4±0.1 | 0.6±0.1 | 44.5±9.6 |
| High dose | 7.0±0.7 | 135.4±21.8 | 392.4±53.6 | 14.3±4.5 | 0.4±0.1 | 0.6±0.1 | 40.2±8.9 |
| Middle dosage | 6.9±0.6 | 140.6±19.5 | 401.6±73.5 | 13.9±3.7 | 0.3±0.1 | 0.7±0.1 | 39.6±6.0 |
| Low dosage | 6.9±0.5 | 145.0±19.8 | 413.6±64.7 | 14.5±4.8 | 0.3±0.1 | 0.7±0.1 | 45.3±9.8 |
Compare no significant difference (P＞0.05) with matched group
Table 8 spring snow is pacified capsule drug withdrawal influence (X ± SD, n=8 are only) to the every hematological indices of rat after 14 days
| Group | Hemogram | The WBC classification | Clotting time | ||||
| RBC×10 12 | Hbg/l | Pit×10 9/1 | WBC×10 9/1 | Neutral % | Lymph % | CT(S) | |
| Matched group | 7.1±0.8 | 139.0±17.6 | 420.5±49.3 | 13.5±3.9 | 0.4±0.1 | 0.6±0.1 | 44.5±9.6 |
| High dose | 7.0±0.7 | 135.4±21.8 | 392.4±5 3.6 | 14.3±4.5 | 0.4±0.1 | 0.6±0.1 | 40.2±8.9 |
| Middle dosage | 6.9±0.6 | 140.6±19.5 | 401.6±73.5 | 13.9±3.7 | 0.3±0.1 | 0.7±0.1 | 39.6±6.0 |
| Low dosage | 6.9±0.5 | 145.0±19.8 | 413.6±64.7 | 14.5±4.8 | 0.3±0.1 | 0.7±0.1 | 45.3±9.8 |
Compare no significant difference (P＞0.05) with matched group
The table 9 spring snow peace continuous gastric infusion of the capsule influence to the every index biochemistry of rat in 90 days (X ± SD, n=12 are only)
| The project group | GPT (U/L) | GOT (U/L) | ALP (U/L) | BUN (mg/dl) | T.P (g/dl) | Alb (g/dl) | GLU (mg/dl) | Crea (mg/dl) | T-Cho (mg/dl) | T-Bil (mg/dl) |
| Matched group | 34.1±6.8 | 161.4± 28.7 | 57.9± 16.3 | 21.2±4.2 | 7.3±0.8 | 3.1±0.3 | 87.0± 14.2 | 1.5±0.2 | 74.8± 14.4 | 0.20± 0.04 |
| High dose | 34.9±9.9 | 168.2± 25.7 | 52.7± 13.2 | 20.3±3.2 | 7.0±0.9 | 3.2±0.3 | 83.2± 13.0 | 1.5±0.2 | 74.2± 15.3 | 0.21± 0.09 |
| Middle dosage | 36.7±8.4 | 167.4± 18.3 | 54.8± 10.9 | 21.4±2.3 | 7.8±0.6 | 3.1±0.4 | 81.7± 18.4 | 1.5±0.1 | 70.1± 11.6 | 0.20± 0.07 |
| Low dosage | 32.8±8.5 | 161.0± 17.4 | 59.4± 17.1 | 23.8±4.3 | 7.2±0.8 | 3.2±0.5 | 86.2± 14.9 | 1.4±0.2 | 72.8± 16.8 | 0.19± 0.06 |
Compare no significant difference (p＞0.05) with matched group
Table 10 spring snow is pacified capsule drug withdrawal influence (X ± SD, n=8 are only) to the every biochemical indicator of rat after 14 days
Compare no significant difference (p＞0.05) with matched group
The continuous gastric infusion of table 11 spring snow peace capsule after 90 days to the sparse influence of Rats Organs and Tissues (X ± SD, n=12 are only)
| Group | The heart | Lung | Liver | Spleen | The adrenal gland | Kidney | Testis (epididymis) (6) | Uterus (ovary) (6) | Brain |
| Matched group | 0.96±0.12 0.35％ | 1.34±0.20 0.48％ | 9.48±1.19 3.4％ | 0.65 ± 0.08 0.23％ | 0.035± 0.009 0.013％ | 1.64±0.20 0.95％ | 3.16±0.36 0.78％ | 0.75±0.03 0.272％ | 1.68±0.24 0.61％ |
| High dose | 1.09±0.18 0.4％ | 1.28±0.18 0.47％ | 9.57±1.02 3.54％ | 0.62 ± 0.06 0.22％ | 0.036± 0.006 0.013％ | 1.59±0.12 0.96％ | 3.24±0.16 0.83％ | 0.72±0.08 0.166％ | 1.71±0.16 0.63％ |
| Middle dosage | 0.97±0.14 0.4％ | 1.23±0.13 0.45％ | 8.60±1.03 3.11％ | 0.56 ± 0.07 0.20％ | 0.036± 0.009 0.013％ | 1.48±0.13 0.90％ | 3.15±0.11 0.78％ | 0.72±0.05 0.261％ | 1.67±0.18 0.61％ |
| Low dosage | 0.99±0.17 0.36％ | 1.29±0.18 0.46％ | 8.97±0.91 3.21％ | 0.55 ± 0.05 0.20％ | 0.035± 0.006 0.013％ | 1.51±0.10 0.90％ | 3.13±0.10 0.76％ | 0.73±0.03 0.262％ | 1.74±0.22 0.62％ |
Compare no significant difference (p＞0.05) with matched group
The drug withdrawal of table 12 spring snow peace capsule after 14 days to the sparse influence of Rats Organs and Tissues (X ± SD, n=8 are only)
| Group | The heart | Lung | Liver | Spleen | The adrenal gland | Kidney | Testis (epididymis) (6) | Uterus (ovary) (6) | Brain |
| Matched group | 1.00±0.18 0..32％ | 1.34±0.24 0.43％ | 11.29±2.64 3.63％ | 0.61±1.03 0.20％ | 0.035± 0.009 0.011％ | 1.80±0.22 0.90％ | 3.57±0.20 0.83％ | 0.82±0.12 0.264％ | 1.83±0.22 0.59％ |
| High dose | 1.06±0.19 0.34％ | 1.37±0.14 0.44％ | 11.72±2.58 3.79％ | 0.59±0.04 0.19％ | 0.036± 0.006 0.012％ | 1.78±0.26 0.90％ | 3.39±0.13 0.77％ | 0.82±0.22 0.265％ | 1.84±0.23 0.60％ |
| Middle dosage | 1.06±0.18 0.35％ | 1.34±0.25 0.44％ | 11.74±3.48 3.82％ | 0.59±0.02 0.19％ | 0.036± 0.004 0.011％ | 1.76±0.18 0.90％ | 3.46±0.24 0.80％ | 0.83±0.12 0.270％ | 1.83±0.33 0.60％ |
| Low dosage | 1.03± 0.19 0.34％ | 1.34± 0.23 0.44％ | 11.68± 2.45 3.89％ | 0.60± 0.03 0.20％ | 0.035± 0.006 0.011％ | 1.79± 0.25 0.90％ | 3.58± 0.11 0.84％ | 0.80± 0.13 0.261％ | 1.81± 0.13 0.59％ |
Compare no significant difference (p＞0.05) with matched group
Clinical report to diseases such as spring blood peace capsule for treating dysfunctional uterine hemorrhages
Summary: test objective: the clinical efficacy and the safety of diseases such as spring blood peace capsule for treating dysfunctional uterine hemorrhage and menoxenia are investigated.Test method: adopt the out-patient clinic and hospitalization patient is divided into treatment group and matched group at random, compare observation.Result of the test: spring blood peace capsule for treating 220 routine patients have tangible curative effect to the improvement of its symptom than matched group.And the rising to hematochrome has certain effect.The safety indexes detection has all been done in this test, proves hepatic and renal function is had no effect, and does not have other side effect.
Key word: spring blood peace capsule dysfunctional uterine hemorrhage menoxenia clinical research
1. case choice criteria
1.1 diagnostic criteria
1.1.1 Western medicine diagnose standard
(1) anovulatory functional bleeding: because ovulation failure, no corpus luteum forms, and endometrial hyperplasia is too much, the irregular metrorrhagia of clinical manifestation, and menstrual period are different in size, and are few for a long time during amount of bleeding, even bleed profusely.Gynecologial examination: cervix uteri hyperemia when hemorrhage, softer, palace mouth pine, uterus are softer, have with a side or the increase of bilateral ovaries capsule.The basal body temperature single phase property, the vaginal exfoliated cell smear anovulatory cycle sexually revises, and hemorrhage preceding 1-2 days cervix uteri mucus presents the lobate crystallization of pteridophyte, and the visible proliferative phase of inner membrance pathologic finding changes or Swiss cheese hyperplasia, and the no secretory phase changes.
(2) ovulation type anovulatory dysfunctional uterine hemorrhage: 1. luteal insufficiency: through preceding endometrial secretion dysfunction; The clinical manifestation menstrual cycle shortens, and how much differs menostaxis through amount; The visible sometimes keratinocyte index of vaginal smear is higher, and cell accumulation, gauffer are not good; The basal body temperature biphasic or bipolar type, shorten luteal phase, below 10 days, or is trapezoidal rising or decline.2. atrophy of corpus iuteum is incomplete, is the secretory phase change through intrauterine film biopsy in the 5th day; Clinical manifestation is that menstrual cycle is normal, and how many menostaxis differs through amount; Basal body temperature is the biphasic or bipolar type that is not true to type, fall delay or decline gradually.
1.1.2 tcm diagnosis standard
1.1.2.1 Chinese medical discrimination: kidney yang deficiency syndrome (with reference to " new Chinese medicine clinical guidance principle ")
(1) hemorrhage suddenly, amount is many or not to the utmost dripping, and color is light or dark red, and matter is rare clearly.
(2) abdominal pain in menstruation, the cold or empty discomfort of weighing down of lower abdomen.
(3) lethargy.
(4) dizzy, stomachache.
(5) shallow complexion.
(6) clear urine in large amounts, big loose stool is thin.
(7) fat light, the white and thin fur of body of the tongue.
(8) deep,thready and forceless pulse.
More than (1), (2) must possess, have concurrently all the other 4 promptly diagnosable.
1.1.2.2 mild symptoms weight classification standard sees Table 13
Table 13
| Symptom | Gently | In | Heavy |
| Amount of bleeding is many | Wrap dripping not to the utmost 5-7 days with paper one every day | Wrap dripping not to the utmost 7-10 days with paper two every day | Use the paper three guarantees every day, dripping not to the utmost more than 10 days |
| Abdominal pain in menstruation | Stomachache can be stood | Stomachache needs to have a rest | The thing pain relieving of need taking medicine |
| The spirit Mi that withers | Fatigue and weak | Lassitude | Drowsy |
| Dizzy | Idol has dizzy | Dizzyly need not have a rest | Need bed |
| Shallow complexion | White | The sallow profit of owing | Sallow and dark |
| Clear urine in large amounts, big loose stool is thin | Every day 2-3 time | Every day 4-5 time | Every day is more than 5 times |
| Body of the tongue is fat light, white and thin fur | Pale tongue, white and thin fur | Corpulent tongue matter is light, and tongue is little greasy | Enlarged tongue is light, gums, and tongue is greasy in vain |
| Deep,thready and forceless pulse | Carefully unable | Heavy unable | Heavy carefully unable |
| Hematochrome | 10g | 8g | 6g |
| The nail fold microcirculation | Slight blood stasis | The moderate blood stasis | The severe blood stasis |
1.2 include the case standard in:
In meeting, Western medicine diagnose standard and Chinese medical discrimination typing standard and go up the ring seraglio blood person of increasing, all can include the test case in.
1.3 get rid of the case standard:
(1) confirms by gestation tumor, wound or whole body mathematics disease causer on inspection.
(2) age is person below 14 years old or more than 50 years old, or women breast-feeding their children, to this medicine allergy sufferers.
(3) be associated with serious primary disease such as cardiovascular, liver, kidney and hemopoietic system, psychotic.
(4) do not meet the standard of including in, not medication in accordance with regulations can't be judged that curative effect or data are not congruent to affect the treatment or safety judgement person.
2. observation index:
2.1 safety observation index:
2.1.1 general health check-up project
2.2 health giving quality observation index:
2.2.1 treatment group and matched group doing well,improving contrast situation
3. EXPERIMENTAL DESIGN
3.1 medicine:
Treatment group: spring blood peace capsule
Matched group: YIMU TIAOJING WAN
3.2 usage: treatment group: oral, one time 4,3 times on the one.
The treatment group: oral, one time 4,3 times on the one.
Matched group: oral, one time 10 ball, 1-3 time on the one.
3.3 the course of treatment: be a course of treatment all around, observed for two courses of treatment continuously.
3.4 treatment requires: do not add during the medication with hemostasis, the pain relieving and the medicine of enriching blood are in order to avoid influence is judged when analyzing curative effect.
3.5 observed and recorded, summary require:
By the clinical study design requirement, unified form is made itemized record, conscientiously finishes writing case history, should note observing untoward reaction, and tracing study.After the off-test, can not alter case history arbitrarily, various data must be done statistical procedures.
4. curative effect determinate standard:
4.1 traditional Chinese medical science disease curative effect determinate standard
4.1.1 clinical recovery: after the control over bleeding, continuous 3 menstrual cycle, menstrual period, blood volume are all normal, and subjective symptoms disappears, and hematochrome can recover normally to ovulate more than 10g, is no less than 12 days luteal phase.
4.1.2 produce effects: after the control over bleeding, menstrual cycle, blood volume are normal substantially, but menstrual period still at 7-10 days, subjective symptoms disappears substantially, hematochrome is the above person of 10g.
4.1.3 effectively: menstrual cycle, menstrual period, part subjective symptoms be improved significantly, oligemia, hematochrome is the above person of 8g.
4.1.4 it is invalid: above every improvement of all not having.
4.2 safety evaluatio standard
One-level: safety, there is not any untoward reaction.
Secondary: compare safety,, need not do any processing, can continue administration if any untoward reaction.
Three grades: safety problem is arranged, moderate untoward reaction is arranged, can continue administration after processing.
Level Four: because of test is ended in untoward reaction.
5. statistical procedures:
Measurement data adopts the t check
6. clinical physical data
6.1 the case source: select my the special outpatient clinic patient of institute 300 examples, wherein 220 examples are organized in treatment, matched group 80 examples.
6.2 wedding is denied, age distribution, sees Table 14
Table 14 a liang group patient wedding is denied, the age structure distribution table
| The example number | Married | Unmarried | Below 20 years old | 20 years old- | 30 years old- | 40 years old- | |
| The treatment group | 220 | 109 | 111 | 101 | 65 | 27 | 27 |
| Matched group | 80 | 38 | 42 | 36 | 24 | 10 | 10 |
Two groups of patients wedding not, age ratio, through X
2Check P＞0.05, difference does not have significance, has comparability.
6.3 sick the kind: clinical symptoms relatively sees Table 15 before two groups of patient treatments
The sick kind of table 15 liang group patient distributes relatively
| The example number | Amount of bleeding is many | Abdominal pain in menstruation | Lethargy | Dizzy | Shallow complexion | |
| The treatment group | 220 | 220 | 220 | 124 | 151 | 188 |
| Matched group | 80 | 80 | 80 | 50 | 58 | 64 |
Clinical symptoms compares before two groups of patient treatments, through X
2Check P＞0.05, difference does not have significance, has comparability.
7. interpretation of result
7. interpretation of result
7.1 two groups of patient's clinical symptoms curative effects relatively, sees Table 16.
7.2 safety indexes detects before and after the treatment of treatment group, sees Table 17.
Table 16 liang group patient clinical symptoms curative effect relatively
| Amount of bleeding is many | Abdominal pain in menstruation | Lethargy | Dizzy | Shallow complexion | ||
| Treatment group matched group | Recovery from illness produce effects enabledisable efficient (%) recovery from illness produce effects enabledisable efficient (%) | 64 72 69 15 93.18 21 21 24 14 82.5 | 59 65 72 24 89.1 20 19 24 17 78.75 | 36 34 42 12 90.3 15 14 13 8 84.0 | 37 42 45 27 82.12 13 15 16 14 75.86 | 49 64 57 18 90.4 20 16 19 9 85.94 |
Two groups of patient's clinical symptoms curative effects are through X
2Check P＜0.01, difference has significance.
Safety indexes detects before and after the treatment of table 17 treatment group
| Before controlling | After controlling | ||
| Routine blood test | Normally | 220 | 220 |
| Unusually | 0 | 0 | |
| Routine urinalysis | Normally | 220 | 220 |
| Unusually | 0 | 0 | |
| Just conventional | Normally | 220 | 220 |
| Unusually | 0 | 0 | |
| Rabat | Normally | 220 | 220 |
| Unusually | 0 | 0 | |
| Electrocardiogram | Normally | 220 | 220 |
| Unusually | 0 | 0 | |
| GPT | Normally | 220 | 220 |
| Unusually | 0 | 0 | |
| BUN Cr | Normally | 220 | 220 |
| Unusually | 0 | 0 | |
Before and after the treatment group treatment to all patients do blood, urine, just conventional sense and electrocardiogram liver, renal function detect, the result does not find These parameters is had a significant effect.
8. untoward reaction
This tests no any untoward reaction among the 360 routine patients, and the safety evaluatio standard is an one-level.
9. rejecting case
This test does not have the case of rejecting.
10. follow up a case by regular visits to
The above case of produce effects is carried out the trimestral statistics of following up a case by regular visits to, see Table 18.
Table 18 Follow-up results
| Add up to | Follow up a case by regular visits to case load | Recurrence | Not recurrence |
| 220 | 100 | 0 | 100 |
11, discussion, brief summary:
The spring blood peace capsule that Tianjin Hongrentang Pharmaceutical Co., Ltd. produces has kidney tonifying Gu Chong, the effect of regulating menstruation, hemostasis.Be mainly used in because of deficiency of the liver and kindey the menorrhagia due to the Chong and Ren channel disorder, abdominal pain in menstruation, adolescence dysfunctional uterine bleeding, last ring back metrorrhagia person.The clinical observation to above disease 220 routine patients is passed through by my institute, prove that this product all has significantly curative effect to improving diseases such as dysfunctional uterine hemorrhage and abdominal pain in menstruation, treatment group and matched group are learned processing P＜0.05 by statistics, and there were significant differences, and it is reliable by its safety of clinical proof, human body is had no side effect, should extensively promote the use of.
The clinical observation of spring blood peace capsule for treating dysfunctional uterine hemorrhage
Summary: test objective: the spring clinical efficacy and the safety of blood peace capsule for treating dysfunctional uterine hemorrhage investigated.Test method: adopt the out-patient clinic and hospitalization patient is divided into treatment group and matched group at random, compare observation.Result of the test: spring blood peace capsule for treating dysfunctional uterine hemorrhage 180 examples, the improvement of its symptom there is tangible curative effect than matched group, wherein treatment is organized clinical total effective rate and is reached 97.78%.And the rising to hematochrome has certain effect.The safety indexes detection has all been done in this test, proves hepatic and renal function is had no effect, and does not have other side effect.
Key word: spring blood peace capsule dysfunctional uterine hemorrhage clinical research
7. case choice criteria
1.1 diagnostic criteria
1.1.1 Western medicine diagnose standard
(3) anovulatory functional bleeding: because ovulation failure, no corpus luteum forms, and endometrial hyperplasia is too much, the irregular metrorrhagia of clinical manifestation, and menstrual period are different in size, and are few for a long time during amount of bleeding, even bleed profusely.Gynecologial examination: cervix uteri hyperemia when hemorrhage, softer, palace mouth pine, uterus are softer, have with a side or the increase of bilateral ovaries capsule.The basal body temperature single phase property, the vaginal exfoliated cell smear anovulatory cycle sexually revises, and hemorrhage preceding 1-2 days cervix uteri mucus presents the lobate crystallization of pteridophyte, and the visible proliferative phase of inner membrance pathologic finding changes or Swiss cheese hyperplasia, and the no secretory phase changes.
(4) ovulation type anovulatory dysfunctional uterine hemorrhage: 1. luteal insufficiency: through preceding endometrial secretion dysfunction; The clinical manifestation menstrual cycle shortens, and how much differs menostaxis through amount; The visible sometimes keratinocyte index of vaginal smear is higher, and cell accumulation, gauffer are not good; The basal body temperature biphasic or bipolar type, shorten luteal phase, below 10 days, or is trapezoidal rising or decline.2. atrophy of corpus iuteum is incomplete, is the secretory phase change through intrauterine film biopsy in the 5th day; Clinical manifestation is that menstrual cycle is normal, and how many menostaxis differs through amount; Basal body temperature is the biphasic or bipolar type that is not true to type, fall delay or decline gradually.
1.1.2 tcm diagnosis standard
1.1.2.1 Chinese medical discrimination: kidney yang deficiency syndrome (with reference to " new Chinese medicine clinical guidance principle ")
(9) hemorrhage suddenly, amount is many or not to the utmost dripping, and color is light or dark red, and matter is rare clearly.
(10) abdominal pain in menstruation, the cold or empty discomfort of weighing down of lower abdomen.
(11) lethargy.
(12) dizzy, stomachache.
(13) shallow complexion.
(14) clear urine in large amounts, big loose stool is thin.
(15) fat light, the white and thin fur of body of the tongue.
(16) deep,thready and forceless pulse.
More than (1), (2) must possess, have concurrently all the other 4 promptly diagnosable.
1.1.2.2 mild symptoms weight classification standard sees Table 19
Table 19
| Symptom | Gently | In | Heavy |
| Primary symptom | 2 minutes | 4 minutes | 6 minutes |
| Amount of bleeding is many | Wrap dripping not to the utmost 5-7 days with paper one every day | Wrap dripping not to the utmost 7-10 days with paper two every day | Use the paper three guarantees every day, dripping not to the utmost more than 10 days |
| Abdominal pain in menstruation | Stomachache can be stood | Stomachache needs to have a rest | The thing pain relieving of need taking medicine |
| Lethargy | Fatigue and weak | Lassitude | Drowsy |
| Dizzy | Idol has dizzy | Dizzyly need not have a rest | Need bed |
| Shallow complexion | White | The sallow profit of owing | Sallow and dark |
| Clear urine in large amounts, big loose stool is thin | Every day 2-3 time | Every day 4-5 time | Every day is more than 5 times |
| Body of the tongue is fat light, white and thin fur | Pale tongue, white and thin fur | Corpulent tongue matter is light, and tongue is little greasy | Enlarged tongue is light, gums, and tongue is greasy in vain |
| Deep,thready and forceless pulse | Carefully unable | Heavy unable | Heavy carefully unable |
| Hematochrome | 10g | 8g | 6g |
| The nail fold microcirculation | Slight blood stasis | The moderate blood stasis | The severe blood stasis |
1.1.2.3 state of an illness grade scale:
Slightly: disease integrated value summation 8-18 branch
Moderate: disease integrated value summation 19-36 branch
Severe: disease integrated value summation 〉=37 minutes
1.2 include the case standard in:
In meeting, Western medicine diagnose standard and Chinese medical discrimination typing standard and go up the ring seraglio blood person of increasing, all can include the test case in.
1.3 get rid of the case standard:
(1) confirms by gestation tumor, wound or whole body mathematics disease causer on inspection.
(2) age is person below 14 years old or more than 50 years old, or women breast-feeding their children, to this medicine allergy sufferers.
(3) be associated with serious primary disease such as cardiovascular, liver, kidney and hemopoietic system, psychotic.
(4) do not meet the standard of including in, not medication in accordance with regulations can't be judged that curative effect or data are not congruent to affect the treatment or safety judgement person.
8. observation index:
2.1 safety observation index:
2.1.1 general health check-up project
2.2 health giving quality observation index:
2.2.1 treatment group and matched group doing well,improving contrast situation
9. EXPERIMENTAL DESIGN
3.1 medicine:
Treatment group: spring blood peace capsule
Matched group: YIMU TIAOJING WAN
3.5 usage:
The treatment group: oral, one time 4,3 times on the one.
Matched group: oral, one time 10 ball, 1-3 time on the one.
3.6 the course of treatment: be a course of treatment all around, observed for two courses of treatment continuously.
3.7 treatment requires:
Do not add during the medication with hemostasis, the pain relieving and the medicine of enriching blood are in order to avoid influence is judged when analyzing curative effect.
3.5 observed and recorded, summary require:
By the clinical study design requirement, unified form is made itemized record, conscientiously finishes writing case history, should note observing untoward reaction, and tracing study.After the off-test, can not alter case history arbitrarily, various data must be done statistical procedures.
10. curative effect determinate standard:
4.2 traditional Chinese medical science disease curative effect determinate standard
4.1.1 clinical recovery: after the control over bleeding, continuous 3 menstrual cycle, menstrual period, blood volume are all normal, and subjective symptoms disappears, and hematochrome can recover normally to ovulate more than 10g, is no less than 12 days luteal phase.
4.1.2 produce effects: after the control over bleeding, menstrual cycle, blood volume are normal substantially, but menstrual period still at 7-10 days, subjective symptoms disappears substantially, hematochrome is the above person of 10g.
4.1.3 effectively: menstrual cycle, menstrual period, part subjective symptoms be improved significantly, oligemia, hematochrome is the above person of 8g.
4.1.4 it is invalid: above every improvement of all not having.
4.2 safety evaluatio standard
One-level: safety, there is not any untoward reaction.
Secondary: compare safety,, need not do any processing, can continue administration if any untoward reaction.
Three grades: safety problem is arranged, moderate untoward reaction is arranged, can continue administration after processing.
Level Four: because of test is ended in untoward reaction.
11. statistical procedures:
Measurement data adopts the t check
12. clinical physical data
6.1 the case source: select my the special outpatient clinic patient of institute 360 examples, wherein 180 examples are organized in treatment, matched group 180 examples.
6.3 wedding is denied, age distribution sees Table 20:
Table 20 a liang group patient wedding is denied, the age structure distribution table
| The example number | Married | Unmarried | Below 20 years old | 20 years old- | 30 years old- | 40 years old- | |
| Treatment group matched group | 180 180 | 85 84 | 95 96 | 83 80 | 53 54 | 22 23 | 22 23 |
Two groups of patients wedding not, age ratio, through X
2Check P＞0.05, difference does not have significance, has comparability.
6.3 symptom integral distributes before two groups of patient treatments, sees Table 21.
Clinical symptoms integration situation before the table 21 liang group treatment (X ± SD)
| The treatment group | Matched group | The P value | |||
| Reciprocal | Integration | Reciprocal | Integration | ||
| The dizzy shallow complexion of many abdominal pain in menstruation of integration amount of bleeding lethargy | 180 180 180 102 124 154 | 4.21±1.12 5.41±2.05 3.31±1.65 4.05±1.24 3.35±2.01 4.21±1.15 | 180 180 180 112 131 143 | 4.28±1.17 5.38±2.24 3.40±1.25 4.13±1.14 3.42±2.11 4.35±1.07 | ＞0.05 ＞0.05 ＞0.05 ＞0.05 ＞0.05 ＞0.05 |
Clinical symptoms integration situation compares before two groups of treatments, through X
2Check P＞0.05, difference does not have significance, has comparability.
7. interpretation of result
7.1 two groups of efficacy analysis see Table 22
Table 22 liang group patient clinical efficacy relatively
| Treatment group (180 example) | Matched group (180 example) | |
| Recovery from illness produce effects enabledisable total effective rate (%) | 65 61 50 4 97.78 | 53 46 55 26 85.56 |
Two groups of patient's clinical symptoms curative effects are through X
2Check P＜0.01, difference has significance.
7.3 symptom integral relatively sees Table 23 behind two groups of patient treatments.
Symptom integral comparison behind the table 23 liang group patient treatment (X ± SD)
| The treatment group | Matched group | The P value | |||
| Reciprocal | Integration | Reciprocal | Integration | ||
| The dizzy shallow complexion of many abdominal pain in menstruation of amount of bleeding lethargy | 180 180 102 124 154 | 3.16±0.74 3.66±1.41 2.01±0.12 3.01±1.02 2.51±1.43 | 180 180 112 131 143 | 3.98±0.84 4.52±1.56 3.21±0.82 3.99±1.23 2.86±1.63 | ＜0.05 ＜0.05 ＜0.05 ＜0.05 ＜0.05 |
Symptom integral relatively through statistics P＜0.05, shows that spring blood peace capsule is better than YIMU TIAOJING WAN behind two groups of patient treatments, and two groups have significant difference.
10. untoward reaction
This tests no any untoward reaction among the 360 routine patients, and the safety evaluatio standard is an one-level.
11. rejecting case
This test does not have the case of rejecting.
12. discussion, brief summary:
The spring blood peace capsule of being produced by Tianjin Hongrentang Pharmaceutical Co., Ltd. has kidney tonifying Gu Chong, the effect of regulating menstruation, hemostasis.Be mainly used in because of liver
Menorrhagia due to the kidney deficiency, Chong and Ren channel disorder, abdominal pain in menstruation, adolescence dysfunctional uterine bleeding, last ring back metrorrhagia person.The clinical observation to above disease 180 routine patients is passed through by my institute, prove that this product has significantly curative effect to improving aspects such as dysfunctional uterine hemorrhage, promotion microcirculation, treatment group and matched group are learned by statistics and are handled P＜0.05, and it is reliable by its safety of clinical proof, human body is had no side effect, should extensively promote the use of.
Tianjin College of Traditional Chinese Medicine two attached internal medicine
The clinical summary of spring blood peace capsule for treating dysfunctional uterine hemorrhage:
Descriptor: spring blood peace capsule dysfunctional uterine hemorrhage curative effect observation clinical research summary: test objective: the clinical efficacy and the safety of the dysfunctional uterine hemorrhage of spring blood peace capsule for treating kidney yang deficiency syndrome are investigated.Test method: the method that adopts self cross-reference.Result of the test: spring blood peace capsule for treating kidney yang deficiency syndrome dysfunctional uterine hemorrhage 300 examples, the improvement of its symptom there is tangible curative effect, wherein clinical recovery 108 examples account for 36%; Produce effects 102 examples account for 34%; Effective 84 examples account for 28%; Invalid 6 examples account for 2%.Learn by statistics and handle P＜0.05.And the hematochrome situation of change before and after the treatment observed, prove can haematochrome increasing, learns processing P＜0.01 by statistics.This is tested among the 300 routine patients and has all done the safety indexes detection, proves hepatic and renal function is had no effect, and does not have other side effect.
13. case choice criteria
1.1 diagnostic criteria
1.1.1 Western medicine diagnose standard
(5) anovulatory functional bleeding: because ovulation failure, no corpus luteum forms, and endometrial hyperplasia is too much, the irregular metrorrhagia of clinical manifestation, and menstrual period are different in size, and are few for a long time during amount of bleeding, even bleed profusely.Gynecologial examination: cervix uteri hyperemia when hemorrhage, softer, palace mouth pine, uterus are softer, have with a side or the increase of bilateral ovaries capsule.The basal body temperature single phase property, the vaginal exfoliated cell smear anovulatory cycle sexually revises, and hemorrhage preceding 1-2 days cervix uteri mucus presents the lobate crystallization of pteridophyte, and the visible proliferative phase of inner membrance pathologic finding changes or Swiss cheese hyperplasia, and the no secretory phase changes.
(6) ovulation type anovulatory dysfunctional uterine hemorrhage: 1. luteal insufficiency: through preceding endometrial secretion dysfunction; The clinical manifestation menstrual cycle shortens, and how much differs menostaxis through amount; The visible sometimes keratinocyte index of vaginal smear is higher, and cell accumulation, gauffer are not good; The basal body temperature biphasic or bipolar type, shorten luteal phase, below 10 days, or is trapezoidal rising or decline.2. atrophy of corpus iuteum is incomplete, is the secretory phase change through intrauterine film biopsy in the 5th day; Clinical manifestation is that menstrual cycle is normal, and how many menostaxis differs through amount; Basal body temperature is the biphasic or bipolar type that is not true to type, fall delay or decline gradually.
1.1.2 tcm diagnosis standard
1.1.2.1 Chinese medical discrimination: kidney yang deficiency syndrome (with reference to " new Chinese medicine clinical guidance principle ")
(17) hemorrhage suddenly, amount is many or not to the utmost dripping, and color is light or dark red, and matter is rare clearly.
(18) abdominal pain in menstruation, the cold or empty discomfort of weighing down of lower abdomen.
(19) lethargy.
(20) dizzy, stomachache.
(21) shallow complexion.
(22) clear urine in large amounts, big loose stool is thin.
(23) fat light, the white and thin fur of body of the tongue.
(24) deep,thready and forceless pulse.
More than (1), (2) must possess, have concurrently all the other 4 promptly diagnosable.
1.1.2.2 mild symptoms weight classification standard sees Table 24
Table 24
| Symptom | Gently | In | Heavy |
| Primary symptom | 2 minutes | 4 minutes | 6 minutes |
| Amount of bleeding is many | Wrap dripping not to the utmost 5-7 days with paper one every day | Wrap dripping not to the utmost 7-10 days with paper two every day | Use the paper three guarantees every day, dripping not to the utmost more than 10 days |
| Abdominal pain in menstruation | Stomachache can be stood | Stomachache needs to have a rest | The thing pain relieving of need taking medicine |
| Lethargy | Fatigue and weak | Lassitude | Drowsy |
| Dizzy | Idol has dizzy | Dizzyly need not have a rest | Need bed |
| Shallow complexion | Anhui is white | The sallow profit of owing | Sallow and dark |
| Clear urine in large amounts, big loose stool is thin | Every day 2-3 time | Every day 4-5 time | Every day is more than 5 times |
| Body of the tongue is fat light, white and thin fur | Pale tongue, white and thin fur | Corpulent tongue matter is light, and tongue is little greasy | Enlarged tongue is light, gums, and tongue is greasy in vain |
| Deep,thready and forceless pulse | Carefully unable | Heavy unable | Heavy carefully unable |
| Hematochrome | 10g | 8g | 6g |
| The nail fold microcirculation | Slight blood stasis | The moderate blood stasis | The severe blood stasis |
1.1.2.4 state of an illness grade scale:
Slightly: disease integrated value summation 8-18 branch
Moderate: disease integrated value summation 19-36 branch
Severe: disease integrated value summation 〉=37 minutes
1.2 include the case standard in:
In meeting, Western medicine diagnose standard and Chinese medical discrimination typing standard and go up the ring seraglio blood person of increasing, all can include the test case in.
1.3 get rid of the case standard:
(1) confirms by gestation tumor, wound or whole body mathematics disease causer on inspection.
(2) age is person below 14 years old or more than 50 years old, or women breast-feeding their children, to this medicine allergy sufferers.
(7) be associated with serious primary disease such as cardiovascular, liver, kidney and hemopoietic system, psychotic.
(8) do not meet the standard of including in, not medication in accordance with regulations can't be judged that curative effect or data are not congruent to affect the treatment or safety judgement person.
14. observation index:
2.1 safety observation index:
2.1.1 general health check-up project
2.1.2 blood, urine, just routine test
2.1.3 the heart, liver, kidney function test
2.2 health giving quality observation index:
2.2.1 doing well,improving situation
2.2.2 hematochrome is measured
2.2.3 examination of nail fold microcirculation
2.2.4 examination of basal body temperature
2.2.5 B-type ultrasonography
15. EXPERIMENTAL DESIGN
3.1 medicine: spring blood peace capsule (being provided by Tianjin Hongrentang Pharmaceutical Co., Ltd.) is provided test drug
3.8 usage: oral, 1 time 4,3 times on the one.
3.9 the course of treatment: be a course of treatment all around, observed for two courses of treatment continuously.
3.10 treatment requires: do not add during the medication with hemostasis, the pain relieving and the medicine of enriching blood are in order to avoid influence is judged when analyzing curative effect.
3.5 observed and recorded, summary require:
By the clinical study design requirement, unified form is made itemized record, conscientiously finishes writing case history, should note observing untoward reaction, and tracing study.After the off-test, can not alter case history arbitrarily, various data must be done statistical procedures.
16. curative effect determinate standard:
4.3 traditional Chinese medical science disease curative effect determinate standard
4.1.1 clinical recovery: after the control over bleeding, continuous 3 menstrual cycle, menstrual period, blood volume are all normal, and subjective symptoms disappears, and hematochrome can recover normally to ovulate more than 10g, is no less than 12 days luteal phase.
4.1.2 produce effects: after the control over bleeding, menstrual cycle, blood volume are normal substantially, but menstrual period still at 7-10 days, subjective symptoms disappears substantially, hematochrome is the above person of 10g.
4.1.3 effectively: menstrual cycle, menstrual period, part subjective symptoms be improved significantly, oligemia, hematochrome is the above person of 8g.
4.1.4 it is invalid: above every improvement of all not having.
4.2 safety evaluatio standard
One-level: safety, there is not any untoward reaction.
Secondary: compare safety,, need not do any processing, can continue administration if any untoward reaction.
Three grades: safety problem is arranged, moderate untoward reaction is arranged, can continue administration after processing.
Level Four: because of test is ended in untoward reaction.
17. statistical procedures:
Measurement data adopts the t check
18. interpretation of result:
6.1 efficacy analysis sees Table 25
Table 25
| The example number | Recovery from illness | Produce effects | Effectively | Invalid | |
| The symptom curative effect | 300 | 108 | 102 | 84 | 6 |
| ％ | 36 | 34 | 28 | 2 | |
| Marriage | |||||
| Married | 141 | 50 | 47 | 39 | 5 |
| Unmarried | 159 | 58 | 55 | 45 | 1 |
| The all ages and classes curative effect | |||||
| 20＜ | 138 | 48 | 44 | 45 | 1 |
| 20- | 88 | 26 | 29 | 31 | 2 |
| 30- | 37 | 18 | 16 | 2 | 1 |
| 40- | 37 | 16 | 13 | 6 | 2 |
| Different course of disease curative effects | |||||
| 5 years＜ | 117 | 43 | 40 | 33 | 1 |
| 5-9 | 86 | 31 | 30 | 24 | 1 |
| 10-14 | 73 | 27 | 25 | 19 | 2 |
| More than 15 years | 24 | 7 | 7 | 8 | 2 |
| Different state of an illness curative effects | |||||
| Gently | 163 | 59 | 56 | 47 | 1 |
| In | 98 | 36 | 34 | 26 | 2 |
| Heavy | 39 | 13 | 12 | 11 | 3 |
6.2 the cardinal symptom integral analysis (X ± SD) that sees Table 26 before and after the treatment
| Symptom | The example number | Before the treatment | After the treatment | Front and back are poor | The P value |
| Amount of bleeding is many | 300 | 4.32±1.03 | 3.26±0.86 | 1.06±0.17 | ＜0.05 |
| Abdominal pain in menstruation | 300 | 5.16±2.12 | 3.87±1.64 | 1.29±0.48 | ＜0.05 |
| Lethargy | 204 | 3.24±1.28 | 2.01±0.36 | 1.23±0.92 | ＜0.05 |
| Dizzy | 184 | 4.27±1.36 | 3.01±1.02 | 1.26±0.39 | ＜0.05 |
| Shallow complexion | 195 | 3.28±2.12 | 2.67±1.64 | 0.61±0.48 | ＜0.05 |
6.3 the hematochrome integral analysis (X ± SD) that sees Table 27 before and after the treatment
| The example number | Before the treatment | After the treatment | Front and back are poor | P |
| 300 | 3.04±0.56 | 2.17±0.50 | 0.87±0.06 | ＜0.01 |
6.4 the nail fold microcirculation improvement situation (X ± SD) that sees Table 28 before and after the treatment
| The example number | Before the treatment | After the treatment | Front and back are poor | P |
| 300 | 5.02±1.23 | 3.84±1.02 | 1.18±0.21 | ＜0.01 |
6.5 safety indexes detects and sees Table 29 before and after the treatment
| Before the treatment | After the treatment | ||
| Routine blood test | Normally | 300 | 300 |
| Unusually | 0 | 0 | |
| Routine urinalysis | Normally | 300 | 300 |
| Unusually | 0 | 0 | |
| Just conventional | Normally | 300 | 300 |
| Unusually | 0 | 0 | |
| Rabat | Normally | 300 | 300 |
| Unusually | 0 | 0 | |
| Electrocardiogram | Normally | 300 | 300 |
| Unusually | 0 | 0 | |
| GPT | Normally | 300 | 300 |
| Unusually | 0 | 0 | |
| BUN | Normally | 300 | 300 |
| Unusually | 0 | 0 | |
| Cr | Normally | 300 | 300 |
| Unusually | 0 | 0 | |
Hepatic and renal function is had no effect safe without toxic side effect after the clinical practice of table 6 explanation spring blood peace capsule.
19. untoward reaction
This tests no any untoward reaction among the 300 routine patients, and the safety evaluatio standard is an one-level.
20. rejecting case
2 examples are rejected in this test altogether, and an example is for merging with the hemostasis Western medicine; One example is a therapy discontinued, so rejected.
21. follow up a case by regular visits to
The above case of produce effects is carried out following up a case by regular visits in three months statistics see Table 30
| The example number | Follow up a case by regular visits to case load | Recurrence | Not recurrence |
| 210 | 80 | 0 | 80 |
22. discuss, brief summary: the spring blood peace capsule of producing by Tianjin Hongrentang Pharmaceutical Co., Ltd. have kidney tonifying solid in, the effect of regulating menstruation, hemostasis.Main term is because of deficiency of the liver and kindey, the menorrhagia due to the Chong and Ren channel disorder, and abdominal pain in menstruation, the adolescence dysfunctional uterine bleeding, last ring is the metrorrhagia person afterwards.The clinical observation to above disease 300 routine patients is passed through by my institute, prove that this product has significantly curative effect to improving above symptom and increasing aspects such as hematochrome, promotion microcirculation, treatment anteroposterior diameter statistical procedures P＜0.05, and it is reliable by its safety of clinical proof, human body is had no side effect, should extensively promote the use of.
Test unit: person: Liang Wenyan (associate chief physician) is responsible in the test of the hospital of traditional Chinese hospital, Tianjin
Test participant: Fan Ruihong (associate chief physician), Ma Lianzhen (main chief physician)
The specific embodiment
Embodiment 1: capsule
Take by weighing raw material by following weight proportion:
Radix Rehmanniae Preparata 300g Semen Plantaginis (processed with salt) 120g Poria 150g Radix Bupleuri 100g Radix Achyranthis Bidentatae 150g Fructus Schisandrae Chinensis (system) 150g Cortex Cinnamomi 60g Rhizoma Alismatis 100g Radix Notoginseng; 100g Radix Aconiti Lateralis Preparata (system) 60g medicine 120g Rhizoma Coptidis 30g Cortex Moutan 100g
Preparation method:
1. Radix Aconiti Lateralis Preparata, Radix Notoginseng, Radix Bupleuri, Cortex Cinnamomi, Rhizoma Coptidis powder are broken into fine powder, cross 80 mesh sieves, standby;
2. with Radix Rehmanniae Preparata, Poria, Rhizoma Alismatis, Semen Plantaginis, Radix Achyranthis Bidentatae, Fructus Schisandrae Chinensis, Rhizoma Dioscoreae, Cortex Moutan water extraction three times, add 6 times of water gagings for the first time, extract 3h; Add for the second time 5 times of water gagings, extract 2h; Add 4 times of water gagings for the third time, extract 1h, merge extractive liquid, filters, and filtrate is condensed into the clear paste that relative density is 1.25～1.30 (65-70 ℃ of heat is surveyed);
3. above-mentioned clear paste is added the fine powder after pulverizing, mixing, drying is ground into fine powder, crosses 24 mesh sieves, and the hard capsule of packing into is made 1160 of capsules, every capsules content of dispersion 1.02～1.32g, promptly.Oral, one time 4,3 times on the one, or follow the doctor's advice.
Embodiment 2: tablet
Take by weighing raw material by following weight proportion:
Radix Rehmanniae Preparata 150g Semen Plantaginis (processed with salt) 60g Poria 75g Radix Bupleuri 50g Radix Achyranthis Bidentatae 75g Fructus Schisandrae Chinensis (system) 75g Cortex Cinnamomi 30g Rhizoma Alismatis 50g Radix Notoginseng 50g Radix Aconiti Lateralis Preparata (system) 30g Rhizoma Dioscoreae 60g Rhizoma Coptidis 15g Cortex Moutan 50g starch is an amount of
Preparation method:
1. Radix Aconiti Lateralis Preparata, Radix Notoginseng, Radix Bupleuri, Cortex Cinnamomi, Rhizoma Coptidis powder are broken into fine powder, cross 80 mesh sieves, standby;
2. Radix Rehmanniae Preparata, Poria, Rhizoma Alismatis, Semen Plantaginis, Radix Achyranthis Bidentatae, Fructus Schisandrae Chinensis, Rhizoma Dioscoreae, Cortex Moutan are used
Water extraction three times adds 6 times of water gagings for the first time, extracts 3h; Add for the second time 5 times of water gagings, extract 2h; Add 4 times of water gagings for the third time, extract 1h, merge extractive liquid, filters, and filtrate is condensed into the clear paste that relative density is 1.2 5～1.30 (65-70 ℃ of heat is surveyed);
3. above-mentioned clear paste is added the fine powder after pulverizing, mixing, it is an amount of to add starch again, and mixed powder is broken into fine powder, crosses 100 mesh sieves, is pressed into 690, and every be the substrate of 1.50g～1.94g, employing polyvinyl alcohol bag film-coat, promptly.Oral, one time 4,3 times on the one.
Embodiment 3: granule
Take by weighing raw material by following weight proportion:
Radix Rehmanniae Preparata 450g Semen Plantaginis (processed with salt) 180g Poria 225g Radix Bupleuri 150g Radix Achyranthis Bidentatae 225g Fructus Schisandrae Chinensis (system) 225g Cortex Cinnamomi 90g Rhizoma Alismatis 150g Radix Notoginseng 150g Radix Aconiti Lateralis Preparata (system) 90g Rhizoma Dioscoreae 180g Rhizoma Coptidis 45g Cortex Moutan 150g
Preparation method:
With Radix Aconiti Lateralis Preparata, Radix Notoginseng, Radix Bupleuri, Cortex Cinnamomi, Rhizoma Coptidis, Radix Rehmanniae Preparata, Poria, Rhizoma Alismatis, Semen Plantaginis,
Radix Achyranthis Bidentatae, Fructus Schisandrae Chinensis, Rhizoma Dioscoreae, Cortex Moutan water extraction three times add 8 times of water gagings for the first time, extract 3h; Add for the second time 6 times of water gagings, extract 2h; Add 6 times of water gagings for the third time, extract 1h, merge extractive liquid, filters, and filtrate is condensed into the clear paste that relative density is 1.25～1.30 (65-70 ℃ of heat is surveyed);
2. above-mentioned clear paste is added ethanol and make and contain the alcohol amount and reach 70%, stir evenly, standing over night is got supernatant, reclaims ethanol, is condensed into relative density and is 1.38～1.41 clear paste.
3. qinghuo reagent, it is an amount of to add equivalent sucrose, dextrin and ethanol, makes granule, drying; Or qinghuo reagent, add dextrin, correctives is an amount of, mixing, spray drying is made sugar-free granule 800g, promptly.Oral, one time 1 bag, every packed 10g, 2 times on the one.
Claims (3)
1, a kind of kidney tonifying CHONG meridian stabilizing and menstruation regulating haemostatic medicament is characterized in that it is the medicament of being made by following materials of weight proportions medicine
10～30 parts of Radix Bupleuri 10-40 of Radix Rehmanniae Preparata 50-80 part Semen Plantaginis 10-30 part Poria part
10～20 parts of 5～15 portions of Rhizoma Alismatis of 20～50 portions of Cortex Cinnamomis of 20～50 parts of Fructus Schisandrae Chinensis of Radix Achyranthis Bidentatae
5～10 parts of 15～30 portions of Rhizoma Coptidis of 9～15 portions of Rhizoma Dioscoreaes of Radix Notoginseng 10-30 part Radix Aconiti Lateralis Preparata
Cortex Moutan 10-30 part.
2, kidney tonifying CHONG meridian stabilizing and menstruation regulating haemostatic medicament according to claim 1 is characterized in that it is the medicament of being made by following materials of weight proportions medicine
30 parts of 20 parts of Radix Achyranthis Bidentataes of 30 parts of Radix Bupleuri of 24 parts of Poria of 60 portions of Semen Plantaginiss of Radix Rehmanniae Preparata
12 parts of 20 parts of Radix Aconiti Lateralis Preparatas of 20 portions of Radix Notoginseng of 12 portions of Rhizoma Alismatis of 30 portions of Cortex Cinnamomis of Fructus Schisandrae Chinensis
20 parts of 6 parts of Cortex Moutans of 24 portions of Rhizoma Coptidis of Rhizoma Dioscoreae.
3, kidney tonifying CHONG meridian stabilizing and menstruation regulating haemostatic medicament according to claim 1 is characterized in that said medicament is capsule, granule, tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100198786A CN100360159C (en) | 2004-07-05 | 2004-07-05 | Kidney benefiting, Chong collateral reinforcing and menstruation regulating hemostat |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100198786A CN100360159C (en) | 2004-07-05 | 2004-07-05 | Kidney benefiting, Chong collateral reinforcing and menstruation regulating hemostat |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1593500A CN1593500A (en) | 2005-03-16 |
| CN100360159C true CN100360159C (en) | 2008-01-09 |
Family
ID=34663103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100198786A Expired - Lifetime CN100360159C (en) | 2004-07-05 | 2004-07-05 | Kidney benefiting, Chong collateral reinforcing and menstruation regulating hemostat |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100360159C (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102600258A (en) * | 2008-04-27 | 2012-07-25 | 李生 | Qingxin Angong pill for clearing heart fire and stopping uterine bleeding |
| CN103830684B (en) * | 2014-03-24 | 2016-02-03 | 雷现莲 | One treats menorrheal pharmaceutical composition and application thereof |
| CN104524116A (en) * | 2015-02-01 | 2015-04-22 | 胡文杰 | Traditional Chinese medicine composition for treating kidney deficiency and blood stasis type endometrial hyperplasia |
| CN105535620A (en) * | 2016-01-13 | 2016-05-04 | 岳晓燕 | Traditional Chinese medicine decoction for treating dysmenorrhea |
-
2004
- 2004-07-05 CN CNB2004100198786A patent/CN100360159C/en not_active Expired - Lifetime
Non-Patent Citations (1)
| Title |
|---|
| 卫生部药品标准中药成方制剂第18册. 卫生部药典委员会，222，卫生部药典委员会. 1998 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1593500A (en) | 2005-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101940740B (en) | Chinese medicinal preparation for treating anemia | |
| CN102240318B (en) | Preparation method and analysis method of traditional Chinese medicine for tonifying qi and increasing breast milk | |
| CN103830577B (en) | A kind of medical composition and its use treating hepatobiliary calculus and urinary stone disease | |
| CN101129773A (en) | Granular formulation, tablet or capsule of black-bone chicken and white phoenix and method of preparing the same | |
| CN100493572C (en) | Composition of medication for treating diabetes | |
| CN101313953B (en) | Medicament composition for treating idiopathic thromboeytopenic purpura and preparation method thereof | |
| CN100360159C (en) | Kidney benefiting, Chong collateral reinforcing and menstruation regulating hemostat | |
| CN100551402C (en) | Chinese medicine composition of treatment mastopathy and preparation method thereof | |
| CN109528980A (en) | A kind of Chinese medicine composition and its pharmacy application for treating Ovary reserve decline disease | |
| CN101732566B (en) | Traditional Chinese medicine compound preparation for tonifying liver and kidney and strengthening bones and muscles | |
| CN101332282B (en) | Traditional Chinese medicine composition for treating gynecologic diseases from kidney deficiency and genitals coldness, and its preparation method | |
| CN105194301A (en) | Traditional Chinese medicine preparation for treating chronic cardiac failure | |
| CN105250556A (en) | Traditional Chinese medicine drug for treating polycystic ovarian syndrome | |
| CN104524292A (en) | Application of traditional Chinese medicine preparation in preparation of medicament for treating obesity | |
| CN100382841C (en) | Composition of Chinese traditional medicine for treating alcoholic hepatitis, and preparation method | |
| CN102125671B (en) | Traditional Chinese medicinal composition for treating gynaecopathia caused by deficiency of the kidney and cold and preparation method thereof | |
| CN104547712A (en) | Traditional Chinese medicine preparation for treating climacteric syndrome and preparation method of traditional Chinese medicine preparation | |
| CN104147180A (en) | Medicine composition for treating immune thrombocytopenic purpura and preparation method thereof | |
| CN103845450A (en) | Application of hawthorns in preparing medicine for treating hyperuricemia, gout and renal insufficiency | |
| CN101658567A (en) | Medicament for treating coronary heart disease and angina and preparation method of granular formulation thereof | |
| CN1315499C (en) | Medicine for treating diabetes and its complications and process for preparing the same | |
| CN100548363C (en) | Medicine of treatment benign prostate hyperplasia and preparation method thereof | |
| CN105030948B (en) | A kind of new application of pharmaceutical composition and its preparation | |
| CN104547738A (en) | Traditional Chinese medicine preparation for treating obesity and preparation method of traditional Chinese medicine preparation | |
| CN104491344A (en) | Use of traditional Chinese medicine preparation in preparing medicines for treating bulging, red, swelling and pain symptoms of eyes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term |
Granted publication date: 20080109 |
|
| CX01 | Expiry of patent term |